IFNA1 and infection: Similarly, pretreating cells with the IFN response inhibitor Ruxolitinib, an established booster for IFN-inducing virus mutants [44, 45], had no positive effect on tc-VLP production or infection, again irrespective of the L genotype (Fig 3(B)).